Crossbridge Bio公司已与制药巨头礼来达成收购协议,旨在加速开发具有突破性的新一代双载荷抗体偶联药物(ADC)技术。此次战略收购将整合Crossbridge Bio在创新疗法领域的专长与礼来的全球资源,共同推动肿瘤治疗领域的边界拓展。
Crossbridge Bio公司已与制药巨头礼来达成收购协议,旨在加速开发具有突破性的新一代双载荷抗体偶联药物(ADC)技术。此次战略收购将整合Crossbridge Bio在创新疗法领域的专长与礼来的全球资源,共同推动肿瘤治疗领域的边界拓展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.